Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis

Journal of Neuroscience Nursing

Volumn 40, Issue 5, 2008, Pages 281-290

  Ollendorf, Daniel A ^a   Castelli Haley, Jane ^b   Oleen Burkey, MerriKay ^b  

^a INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

^b Teva Neuroscience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ARTICLE; DRUG COMBINATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MULTIPLE SCLEROSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 58149296007     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/01376517-200810000-00006     Document Type: Article

References (21)

1. American Medical Association. (2006a). Health care procedure coding system 2007: National level II, Medicare codes. Chicago: Author.
2. American Medical Association. (2006b). International classification of diseases, 9th revision: Clinical modification, 6th edition, 2007. Chicago: Author.
3. Andersen, P. K., Borgan, O., Gill, R. D., & Keiding, N. (1993). Statistical models based on counting processes. New York: Springer-Verlag.
4. Andersen, P. K., & Gill, R. D. (1982). Cox's regression model for counting processes: A large sample study. Annals of Statistics, 10, 1100-1120.
5. Beebe, M., Dalton, J. A., Espronceda, M., Evans, D. D., & Glenn, R. L. (2007). CPT 2007 standard edition: Current procedural terminology. Chicago: American Medical Association.
6. Callas, P. W., Pastides, H., & Hosmer, D. W. (1998). Empirical comparisons of proportional hazards, Poisson, and logistic regression modeling of occupational cohort data. American Journal of Industrial Medicine, 33, 33-47. (Pubitemid 27520066)
7. Gudmundsson, K. R. (1971). Clinical studies of multiple sclerosis in Iceland: A follow-up of previous survey and reappraisal. Acta Neurologica Scandinavica, 48 (Suppl.), 1-78.
8. Hosmer, D. W., & Lemeshow, S. (1999). Applied survival analysis. New York: Wiley Interscience.
9. Klein, J., & Rubingh, C. (2001, June). Improving patient adherence to glatiramer acetate with cetirizine. Abstract from poster session presented at Consortium of MS Centers, Fort Worth, TX.
10. Kurtzke, J. F., Beebe, G. W., & Norman, J. E., Jr. (1979). Epidemiology of multiple sclerosis in U. S. veterans: Race, sex, and geographic distribution. Neurology, 29, 1228-1235.
11. Lhermitte, F., Marteau, R., Gazengel, J., Dordain, G., & Deloche, G. (1973). The frequency of relapse in multiple sclerosis: A study based on 245 cases. Zeitschrift für Neurologie, 205, 47-59.
12. Lindsey, J. K. (1998). Counts and time to events. Statistics in Medicine, 7, 1745-1751.
13. Mazzeo, L., Ricciardi, L., Fazio, M. C., Fogliani, O., Fedele, R., Ferlazzo, E., et al. (2003). Severe urticaria due to recombinant interferon beta-1a [Letter to the editor]. British Journal of Dermatology, 148 (1), 172. (Pubitemid 36114885)
14. Ollendorf, D. A., Jilinskaia, E., & Oleen-Burkey, M. (2002). Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. Journal of Managed Care Pharmacy, 8, 469-476.
15. Pardo, G., Boutwell, C., Conner, J., & Denney, D., for the Oral Antihistamine Study Group (2007, October). Impact of oral antihistamine on local injection-site reactions with glatiramer acetate [Poster presentation]. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, Czech Republic.
16. Patzold, U., & Pocklington, P. R. (1982). Course of multiple sclerosis: First results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurologica Scandinavica, 65, 248-266. (Pubitemid 12074138)
17. ®) induces non-immunologic activation of connective tissue type mast cells. Abstract from poster session presented at American Academy of Allergy, Asthma, and Immunology, New Orleans, LA.
18. Teitelbaum, D., Aharoni, R., Sela, M., & Arnon, R. (1991). Cross reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic glatiramer acetate. Proceedings of the National Academy of Sciences USA, 88, 9528-9532. (Pubitemid 21915664)
19. Webb, C., Teitelbaum, D., Arnon, R., & Sela, M. (1973). In-vivo and in-vitro immunological cross-reaction between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. European Journal of Immunology, 3, 279-286.
20. Wei, L. J., & Glidden, D. V. (1997). An overview of statistical methods for multiple event failure time data in clinical trials. Statistics in Medicine, 16, 833-839.
21. Weinshenker, B. G., Bass, B., Rice, G. P., Noseworthy, J. H., Carriere, W., Baskerville, J., et al. (1989). The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain, 112, 133-146. (Pubitemid 19056478)